Main Conference Day Two 24th February 2010

08.30 Registration And Coffee

09.00 Chair’s Welcome

Cross Industry Perspective to Enable You to Benchmark, Analyse, Assess and Implement Strategic Approaches from the Telecoms Industry to Your Business

09.15 Cross Industry Perspective: Nokia Case Study

Understanding the procedures, processes and strategies from another industry can help widen the potential options and tools for the pharmaceutical industry to combat the production of counterfeit goods. Translating potential solutions from the telecoms industrycan provide useful solutions that can positively impact the anti-counterfeit strategies within the pharmaceutical industry. Specific discussion from Lucy includes:

  • What can we learn from those outside the industry?
  • Nokia: What can we apply to pharmaceuticals and how we managed to successfully combat counterfeiting practices
  • Similarities between telecoms and pharmaceuticals examples of best practice for future implementation

Lucy Nichols
Global Director, Brand Protection
Nokia

Regulatory and Government Agency Overview: Understanding Decisions to Ensure Your Company Complies and Implements Best Practice in combating Counterfeiters

10:00 The MHRA’s Perspective: Stakeholder And Law Enforcement Collaboration

Michael Deats
Group Manager, Enforcement Group, Inspection, Enforcement and Standards Division
Medicines and Healthcare Products Regulatory Agency (MHRA)

10.45 Technology Spotlight Session

11.15 Networking Coffee Break

11.45 Drug Counterfeits – A Challenge To Public Health

Tassilo Korab
Executive Director
European Healthcare Compliance Council

12.30 Manufacturer Interaction With Customs: A Johnson And Johnson Perspective

Karl Boonen
Executive Director Healthcare Solutions and Business Support
Janssen-Cilag EMEA

Chris Verleye
Senior Counsel
Johnson and Johnson

13.15 Networking Lunch

In-House Manufacturers Overview: A Real-Life Example Of Implementing A Track And Trace Program In The USA

  • Securing the distribution process of a sensitive drug from the manufacturing plant to the dispensing point
  • Upgrading the system for use with datamatrix and according to e-pedigree legislation
  • Sharing feedback: what went well and what could have been done better

Sébastien Mauel
Head of Product Security
Merck Serono

12.45 Manufacturer Interaction With Customs: A Johnson And Johnson Perspective

The operational, logistic and legal issues are always a matter of concern for pharmaceutical companies. When dealing with the issue of anti-counterfeiting the collaboration with external parties such as customs, plays a big part in this role, Karl and Chris, will give the manufacturers perspective of the real benefits of collaborating with external authorities such as customs and the particular benefit this collaboration has given Johnson and Johnson so far.

This dual presentation includes:

  • Partnership with customs in our fight against counterfeitings
  • Why now?
  • Why DVP (Drug Validation Portal)?
  • Potential next steps

Karl Boonen
Executive Director, Johnson and Johnson And Chris Verleye, Senior Counsel
Johnson and Johnson

13.15 Networking Lunch

14.30 The AstraZeneca Strategy For Addressing Illegal Trade, And Adapting Strategic Responses

Claire, a specialist in change as well as anti-counterfeiting, will discuss the successes of AstraZeneca’s strategy and the practicalities of adapting that strategy to best combat counterfeit trade. Topics include:

  • An overview of the AstraZeneca strategic response and reasoning behind the response
  • Adapting the response in light of experience, an effective analysis of your current strategy in order to identify the correct areas to change
  • Engaging with internal and external stakeholders to drive change

Claire Barber
Global Projects & Change Director
AstraZeneca

International Policy and Timelines in Changing Policy to Ensure You are Implementing the Correct Tools and Technologies for Your Company’s Success

15.15 A Real-Life Example Of Implementing A Track And Trace Program In The USA

Sébastien Mauel
Head of Product Security
Merck Serono

15.40 Networking Coffee Break

16.10 Europol - A Co-Ordinated International Law Enforcement Response

Europol has played a key part in the co-operating with external parties and coordinating to ensure all measures to stop counterfeit goods reaching the market are made now. Whilst specific countries such as German customs have had success with projects such as “Project Blue”, these initiatives would not have achieved their intended outcome without the co-operation of external parties and stakeholders. Chris Perryman, explains the part Europol has to play, and the talk will feature the following points;

  • The threat posed by counterfeit pharmaceuticals
  • Strategic co-operation
  • Operational co-operation
  • Results of co-operation via Europol

Chris Perryman
AWF COPY Team
Europol

16.55 Roundtables: International Health Authorities Policy Panel

I am sure you are all too aware that pharmaceutical anti-counterfeiting doesn’t stop within Europe. Whilst certain countries in Europe seem to be more impacted than others, pharmaceutical anti-counterfeiting in countries such as Nigeria, China and India, are still impacting the European supply chain and with issues such as parallel trading it is really important to understand:

  • The intricacies of the policy in place in these countries
  • Time lines for change in order for you to assess analyse and discover how the changes within this potential policy may impact your anti-counterfeiting strategy

Facilitated by day one and two speakers

17.40 Chair’s Closing Remarks

[ Register Now ]